In the Latest Big Pharma/RNAi Alliance, Alcon Inks Deal with Dharmacon for Eye Diseases

For Dharmacon, it represents the first step towards moving beyond its role as simply an RNAi oligo and tool provider in a market that has become increasingly saturated with competition. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.